Opioids are a class of drugs that affect the brain, including by relieving pain, and they are extremely addictive. Policymakers can combat the opioid epidemic by:
- limiting inappropriate use of prescription opioids;
- reducing the flow of illicit opioids (like heroin);
- helping people seek treatment for opioid misuse; and
- deploying harm reduction tools that blunt the risks of death, illness, or injury.
These strategies are reflected in ongoing work at the federal, state, and local levels.
- 130 Americans die from an opioid overdose every day, and millions of Americans report misuse of opioids.
- Policymakers can combat the epidemic by reducing the number of people who receive prescription opioids and reducing the volume of prescription and non-prescription opioids released into communities.
- Addressing the opioid epidemic requires helping the millions of Americans who are misusing opioids today by making treatment more widely available and using harm reduction strategies.
A Closer Look
Opioids include prescription drugs like oxycodone as well as illicit drugs like heroin. These drugs are extremely addictive. While opioids have existed for hundreds of years, health care providers generally limited their use because of concerns about addiction. However, beginning in the 1990s, a constellation of factors led to increased use of prescription opioids, including growing attention to pain management as an important clinical goal and the manufacture and marketing of a new generation of prescription opioids. The rise in prescriptions was also associated with increased availability of illegal opioids like heroin.
We have seen a dramatic rise in illness and death associated with improper use of opioids. According to federal data:
- 12 million people reported misuse of opioids in 2016.
- Estimates suggest that 2.1 million people struggled with opioid use disorder in 2017.
- Doctors wrote 59 opioid prescriptions per 100 residents in 2017, down from a peak of about 81 per 100 residents in 2010.
- There were 140,000 visits to an emergency room because of an opioid overdose in 2015.
- About 48,000 people died from an opioid overdose in 2017, or about 130 people per day.
For context, the number of deaths from opioid overdose in 2017 is comparable to the number of deaths from HIV-related causes at the height of that epidemic in the 1990s, and is nearly 8 times larger than the number of HIV deaths today.
What can policymakers do to combat the opioid epidemic?
Addressing a public health crisis of this magnitude is a complex undertaking. Policymakers can work to prevent people from becoming addicted to opioids and to help people who are already misusing opioids to treat their addiction and minimize the risk of death or other harm. In general, there are four kinds of strategies:
Limiting prescription opioids
For the last 15 years, physicians have been prescribing opioids at high rates. In a handful of states, there is more than one opioid prescription per person each year. Some overprescribing is the result of “pill mills”—unethical providers who write prescriptions with indifference to clinical need. Other times, patients may be visiting multiple prescribers to seek prescription opioids. And in still other cases, providers may be using prescription opioids to combat pain when other treatments, smaller quantities, or less potent drugs may suffice.
The overuse of prescription opioids fuels the epidemic in two ways. First, it introduces patients (even when taking these drugs as prescribed) to an addictive substance, which creates the risk of subsequently developing opioid use disorder. Second, it creates a flow of opioids that can be diverted from their intended purpose.
Therefore, policymakers can take actions that reduce opportunities for misuse of prescription opioids. These include:
- Prescription Drug Monitoring Programs (PDMPs). 49 states and the District of Columbia have established a PDMP, a statewide database that shows every opioid prescription. Health care providers can check (or be required to check) this database before writing a prescription, allowing them to see if the patient has received opioids from other doctors.
- Prescriber limits. In 2016 the federal government released guidelines for prescribing opioids for chronic pain outside of active cancer treatment, palliative care, and end-of-life care. Consistent with these guidelines, many states have made it unlawful for providers in many circumstances to write opioid prescriptions that exceed a particular strength or that span longer than a few days or weeks.
- Law enforcement. Cracking down on “pill mills” and other unethical and illegal overprescribing behavior by health care providers can have a major impact on the volume of prescription opioids.
- Stakeholder education. Provider education can emphasize the appropriate and limited role of opioids. Similarly, insurance companies can be encouraged to cover non-drug pain therapies and to monitor their own data for early warning signs of opioid misuse or prescriber misconduct.
All of these strategies must balance opioids’ valuable benefits in pain control against the risk of misuse. Policymakers should always be cognizant of the possibility that they could enact too many or the wrong kinds of restrictions and leave patients unnecessarily struggling with unmanaged pain.
Reducing the flow of illicit opioids
Many opioid deaths are associated with illicit opioids like heroin and illegally produced fentanyl. (Fentanyl, in particular, is an extremely potent and deadly opioid, and its use is on the rise.) Although there are no simple solutions, many communities have invested in funding for law enforcement efforts that target large scale opioid distribution.
Collaborative efforts that work across borders and jurisdictions are necessary to share up-to-date information. The federal government has helped facilitate intelligence sharing across agencies, which can help federal, state, and local law enforcement identify and respond to emerging trends. Federal law enforcement agencies have also brought cases against major drug trafficking organizations using this shared information.
In addition, communication among law enforcement, public health professionals, and first responders about distribution patterns can help target public health efforts.
A variety of treatment options exist to help people already suffering from opioid use disorder. Experts believe that the most effective treatment for many people will be “medication assisted treatment,” or MAT. MAT involves taking one or more drugs that are intended prevent opioid misuse. These drugs can reduce cravings for opioid misuse or prevent opioids from causing a “high.” (Some of the drugs involved in MAT are themselves opioids.) MAT also involves structured counseling and other support.
Only 17.5% of people who could benefit from specialized treatment for prescription opioid use disorder received it in 2016. Obstacles to treatment include lack of insurance coverage for treatment, difficulty finding a provider, and patients’ unwillingness to begin treatment. Strategies to promote treatment include:
- Medicaid expansion. In states that have expanded Medicaid under the Affordable Care Act , any low-income individual can enroll in Medicaid, where they will have coverage for a wide variety of opioid treatment options. Many studies have linked Medicaid expansion to improved take-up of MAT therapies. Therefore, in states that have not yet expanded, Medicaid expansion can help many people access treatment.
- Payments for opioid treatment. Policymakers can also provide funding for opioid treatment for people who are uninsured or underinsured. This can include supporting treatment directly (like paying for MAT therapies) or subsidizing services like housing support that can make treatment more successful.
- Peer support. There are many successful models of peer support interventions where people in treatment help encourage others with opioid use disorder initiate treatment and offer support throughout recovery. Peer supports can bridge the gap between the clinical treatment setting and everyday life.
- Treatment and the criminal justice system. The federal government has also recently released new guidance to states on MAT in the criminal justice system, suggesting that criminal justice agencies may choose to provide MAT in-house, or partner with community-based providers to deliver treatment to voluntary participants in custody. Establishing relationships with community-based providers can help ensure continuity of care once individuals have been released from incarceration.
The federal government has provided significant grants to states, and states and local communities are also investing their own resources in these kinds of treatment strategies. Policymakers may also recognize that injury and death associated with opioid use has been concentrated in communities experiencing lower rates of economic growth, which can help target treatment investments.
Finally, policymakers can also focus on “harm reduction” – that is, mitigating the risk that opioid use disorder will cause illness, injury, or death. This includes:
- Naloxone. One of the most important tools is broad availability of naloxone, a drug that can immediately reverse the effects of an opioid overdose. Making naloxone widely available to first responders (including police officers) and to individuals can dramatically reduce the risk of death from overdose.
- Needle exchange. Opioid misuse often involves intravenous drug use, which can lead to transmission of infections like HIV and Hepatitis C. Making clean needles available can reduce the risk of these diseases, and can connect drug users with vital health care services. Needle exchange programs can also link individuals with opioid use disorder to treatment services when they are ready to seek treatment.
Carol Graham discusses the causes and consequences of the opioid crisis and what policymakers can do to address it.
“The substance use crisis, particularly opioid misuse crisis, is the most important public health challenge of our time,” said Admiral Brett P. Giroir, M.D., the assistant secretary for health at the U.S. Department of Health and Human Services, at a recent Brookings event on the opioid crisis. Adm. Giroir’s remark occurred during a panel discussion […]